Rhumbline Advisers Elevation Oncology, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 70,035 shares of ELEV stock, worth $42,721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,035
Previous 64,606
8.4%
Holding current value
$42,721
Previous $38,000
5.26%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ELEV
# of Institutions
71Shares Held
39.1MCall Options Held
100Put Options Held
3.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.66 Million0.21% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.9 Million0.21% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.15 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA2.97MShares$1.81 Million0.06% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.73 Million0.6% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $14.2M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...